PMID- 35773047
OWN - NLM
STAT- MEDLINE
DCOM- 20220719
LR  - 20240306
IS  - 1558-1977 (Electronic)
IS  - 0889-8588 (Linking)
VI  - 36
IP  - 4
DP  - 2022 Aug
TI  - Genome-Edited T Cell Therapies.
PG  - 729-744
LID - S0889-8588(22)00027-2 [pii]
LID - 10.1016/j.hoc.2022.03.006 [doi]
AB  - Chimeric antigen receptor (CAR) T-cells are widely being investigated against 
      malignancies, and allogeneic 'universal donor' CAR-T cells offer the possibility 
      of widened access to pre-manufactured, off-the-shelf therapies. Different 
      genome-editing platforms have been used to address human leukocyte antigen (HLA) 
      barriers to generate universal CAR-T cell therapy and early applications have 
      been reported in children and adults against B cell malignancies. Recently 
      developed Clustered Regularly Interspaced Short Palindromic Repeats 
      (CRISPR)-based systems and related technologies offer the prospect of enhanced 
      cellular immunotherapies for a wider range of hematological malignancies.
CI  - Copyright (c) 2022 Elsevier Inc. All rights reserved.
FAU - Ottaviano, Giorgio
AU  - Ottaviano G
AD  - Infection, Immunity & Inflammation Department, UCL Great Ormond Street Institute 
      of Child Health, University College London Institute of Child Health, 30 Guilford 
      Street, London WC1N 1EH, UK.
FAU - Qasim, Waseem
AU  - Qasim W
AD  - Infection, Immunity & Inflammation Department, UCL Great Ormond Street Institute 
      of Child Health, University College London Institute of Child Health, 30 Guilford 
      Street, London WC1N 1EH, UK. Electronic address: w.qasim@ucl.ac.uk.
LA  - eng
GR  - MR/S019022/1/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20220627
PL  - United States
TA  - Hematol Oncol Clin North Am
JT  - Hematology/oncology clinics of North America
JID - 8709473
SB  - IM
MH  - *CRISPR-Cas Systems
MH  - Child
MH  - Gene Editing/methods
MH  - Humans
MH  - Immunotherapy, Adoptive/methods
MH  - *Neoplasms/therapy
MH  - T-Lymphocytes
OTO - NOTNLM
OT  - Base editor
OT  - CRISPR/Cas9
OT  - Chimeric antigen receptor
OT  - Cytidine deamination
OT  - Genome editing
OT  - T cell therapies
EDAT- 2022/07/01 06:00
MHDA- 2022/07/20 06:00
CRDT- 2022/06/30 22:03
PHST- 2022/07/01 06:00 [pubmed]
PHST- 2022/07/20 06:00 [medline]
PHST- 2022/06/30 22:03 [entrez]
AID - S0889-8588(22)00027-2 [pii]
AID - 10.1016/j.hoc.2022.03.006 [doi]
PST - ppublish
SO  - Hematol Oncol Clin North Am. 2022 Aug;36(4):729-744. doi: 
      10.1016/j.hoc.2022.03.006. Epub 2022 Jun 27.